# GT Medical Technologies Closes Oversubscribed $100 Million Series E After Pivotal ROADS Trial Win at ASCO 2026

> financing · REPORTED · 2026-06-09

On June 9, 2026, GT Medical Technologies closed an oversubscribed $100 million Series E led by Viking Global Investors, following presentation of the ROADS randomized controlled trial at ASCO 2026, which showed that its FDA-cleared GammaTile bioresorbable brain-tumor radiotherapy implant reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard care; proceeds will fund commercial expansion and the BRIDGES glioblastoma trial.

- Company: GT Medical Technologies
- Sector: medical devices
- Primary source: https://www.biospace.com/press-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.